Ubrelvy was marketed as a breakthrough - a newer migraine drug that blocks CGRP without the cardiovascular risks of triptans. No chest tightness. No rebound headache risk. A cleaner mechanism for stopping a migraine in progress.
For some people, it delivers on that promise. But for many others, Ubrelvy does nothing, or works inconsistently, or helped once and then seemed to stop. If that's your experience, the explanation is usually more specific than "it just doesn't work for you."
Ubrelvy has particular vulnerabilities - around timing, dose, food, and drug interactions - that make it more finicky than many people realize. Understanding these can mean the difference between a drug that fails and one that works.
Key distinction
Ubrelvy is acute-only. Unlike Nurtec (rimegepant), which is approved for both acute treatment and prevention, Ubrelvy has no preventive indication. It blocks CGRP receptors during an active attack, but it is not designed to reduce how often migraines occur. If you were prescribed Ubrelvy expecting it to lower your overall migraine frequency, that is not what it does.
What Ubrelvy Actually Does - and Doesn't Do
Ubrelvy (ubrogepant) is a gepant - a small-molecule CGRP receptor antagonist. During a migraine attack, trigeminal nerve fibers release CGRP, which dilates blood vessels, promotes neurogenic inflammation, and sensitizes pain pathways. Ubrelvy blocks the receptor CGRP binds to, interrupting this cascade while it's happening.
Unlike triptans, Ubrelvy does not constrict blood vessels. This makes it an option for people with cardiovascular risk factors who cannot safely take triptans. But it also means Ubrelvy lacks the brute-force vasoconstriction that triptans use to overpower a late-stage attack.
Ubrelvy's action is narrower: it blocks one receptor, during one window, for one attack. That precision is its strength in the right scenario - and its limitation in the wrong one.
Why Ubrelvy Doesn't Work for Some People
1. You're taking it too late in the attack
Timing matters more with Ubrelvy than with most acute migraine medications. The ACHIEVE clinical trials showed significantly better pain-freedom rates when ubrogepant was taken early - ideally within the first hour of attack onset. Once central sensitization sets in (when your scalp hurts, light becomes unbearable, and the pain has fully established itself), peripheral CGRP blockade becomes much less effective.
Triptans can sometimes muscle through a late-stage attack because vasoconstriction physically reduces blood vessel dilation. Ubrelvy does not have this mechanism. It works by blocking a signaling molecule, and once the downstream cascade is fully activated, blocking the signal at its source has diminishing returns. If you've been waiting until the pain is moderate or severe before taking Ubrelvy, that delay alone may explain why it's failing.
2. Food is interfering with absorption
This is one of the most overlooked reasons Ubrelvy fails. A high-fat meal delays Ubrelvy's absorption significantly, pushing back the time to peak blood levels by hours. During a migraine, when every minute counts, that delay can be the difference between catching the attack and missing the window entirely.
Compounding this problem: migraines themselves cause gastroparesis - slowed stomach emptying. Most people don't realize their stomach nearly stops processing during a migraine. If you took Ubrelvy after eating, during a migraine that's already slowing your gut, the drug may be sitting in your stomach instead of reaching your bloodstream.
Practical takeaway: take Ubrelvy on an empty stomach or with only a light, low-fat snack. Keep it accessible so you can take it immediately at the first sign of an attack - not after you've eaten dinner.
3. The dose may be too low
Ubrelvy comes in 50mg and 100mg tablets. Many providers start patients at 50mg, which is reasonable as an initial approach. But the ACHIEVE I and II trials showed that 100mg consistently produced higher rates of pain freedom at two hours compared to 50mg. Some people simply need the higher dose for adequate CGRP receptor blockade.
If you've only tried 50mg and concluded that Ubrelvy doesn't work, you may not have given it a fair trial. A second dose of 50mg can also be taken at least two hours after the first if the migraine persists or returns - but many patients aren't told this. The question of whether to start at 100mg or use a second 50mg dose is worth discussing with your provider.
4. A drug interaction is changing your blood levels
Ubrelvy is metabolized by the CYP3A4 enzyme system in the liver. This is a busy enzyme - it processes a large number of common medications. When another drug that inhibits or induces CYP3A4 is added to your regimen, it can dramatically change how much active ubrogepant is actually circulating in your blood.
Strong CYP3A4 inhibitors (certain antibiotics like clarithromycin, antifungals like ketoconazole, and HIV protease inhibitors) are contraindicated with Ubrelvy entirely. But moderate inhibitors and inducers are more common and easier to miss:
- CYP3A4 inhibitors (increase Ubrelvy levels, may require dose reduction): fluconazole, erythromycin, verapamil, diltiazem, grapefruit juice
- CYP3A4 inducers (decrease Ubrelvy levels, may make it ineffective): rifampin, phenytoin, carbamazepine, St. John's wort
This is a hidden reason Ubrelvy "stops working." If you started a new medication - or even began drinking grapefruit juice regularly - around the time Ubrelvy became less effective, that timing is not a coincidence. Ask your pharmacist to check for CYP3A4 interactions with your full medication list.
5. CGRP isn't the primary driver of your attacks
Even with perfect timing, the right dose, no food interference, and no drug interactions, Ubrelvy will still fail if CGRP is not the dominant mechanism behind your migraines. CGRP is one pathway in a system with many. Migraines can be driven by:
- Histamine overload - where mast cell activation drives vasodilation and neuroinflammation through a different pathway entirely
- Hormonal instability - where estrogen withdrawal triggers cascades that may involve CGRP but are primarily driven by hormonal shifts
- Autonomic dysfunction - where the issue is blood pressure regulation, not CGRP signaling
- Central sensitization - where pain processing has shifted into the brainstem and cortex, beyond the reach of peripheral CGRP blockade
When CGRP is more of a downstream effect than a root cause, blocking it with Ubrelvy treats a symptom of the cascade rather than its origin. This is actually useful diagnostic information - it narrows the search for what is driving your attacks.
Ubrelvy vs Nurtec: Same Class, Different Drugs
Both are gepants. Both block CGRP receptors. But they are not interchangeable, and failing on one does not necessarily mean the other will also fail.
Approval scope: Ubrelvy is acute-only. Nurtec is approved for both acute treatment and prevention (every-other-day dosing). If you need a gepant that also reduces attack frequency, Ubrelvy is the wrong tool.
Formulation: Nurtec is an orally disintegrating tablet (ODT) that dissolves on the tongue. Ubrelvy is a standard tablet swallowed with water. During a migraine with nausea and gastroparesis, the ODT formulation may have a practical absorption advantage.
Drug interactions: Both are metabolized by CYP3A4, but with different sensitivities. A CYP3A4 interaction that undermines Ubrelvy may affect Nurtec differently. This is worth reviewing with a pharmacist if you suspect an interaction is involved.
If Ubrelvy failed: Before concluding that gepants don't work for you, consider whether the failure was pharmacokinetic (timing, dose, food, interaction) or pharmacodynamic (CGRP is not your primary driver). If the former, fixing the practical issues or trying Nurtec may help. If the latter, neither gepant is likely to be the answer.
When Ubrelvy Does Work
Ubrelvy is not a bad drug - it's a specific one. It works well in scenarios that align with its mechanism and pharmacokinetics:
- • Mild-to-moderate attacks caught early - taken within the first hour of onset, before central sensitization develops, Ubrelvy has its best chance of stopping the attack
- • People who cannot take triptans - cardiovascular risk factors, history of stroke or heart disease, or intolerable triptan side effects make Ubrelvy a meaningful alternative
- • Triptan side effect avoidance - people who get chest tightness, jaw clenching, fatigue, or worsened nausea from triptans often tolerate gepants much better
- • CGRP-driven attacks without heavy central sensitization - attacks where the pain stays moderate and doesn't progress to the "everything hurts" phase respond better to peripheral CGRP blockade
- • As a complement, not a replacement - some people use Ubrelvy for milder attacks and keep a triptan for severe ones. Matching the tool to the severity and type of attack often works better than using one medication for everything
What to Discuss With Your Clinician
If Ubrelvy isn't working as expected, these questions can help guide a more productive conversation:
- • Whether stepping up to 100mg is appropriate if you've only tried 50mg
- • Whether any of your current medications interact with CYP3A4 (your pharmacist can run this check)
- • Whether Nurtec might be worth trying for its different formulation or dual acute/preventive approval
- • Whether a CGRP monoclonal antibody (Aimovig, Ajovy, Emgality) could provide continuous CGRP suppression that an acute-only gepant cannot
- • Whether your migraine pattern suggests a different primary driver - histamine, hormonal, vascular - that CGRP blockade alone won't address
- • Whether reducing overall migraine load (sleep, stress, hydration) could improve Ubrelvy's effectiveness for attacks that still break through
The Part Most People Miss
Ubrelvy failing is not the same as being out of options. It's information.
If the failure is pharmacokinetic - wrong timing, wrong dose, food interference, drug interaction - those are fixable problems. Many people abandon Ubrelvy before they've actually optimized how they're using it.
If the failure is pharmacodynamic - CGRP just isn't your primary driver - that's equally valuable. It tells you to stop cycling through CGRP-class drugs and start investigating what is driving your attacks. Whether that's medication overuse, histamine, hormonal instability, autonomic dysfunction, or a combination of load factors pushing you over your threshold, identifying the actual mechanism is how you move forward.
This guide is for education and pattern-recognition only. It is not medical advice and is not a plan to start, stop, or change any medication, supplement, or test. Always discuss treatment decisions with a licensed clinician who knows your history.
Clinical and Review Articles
- Dodick DW et al. Ubrogepant for the treatment of migraine. New England Journal of Medicine. 2019;381(23):2230-2241. (ACHIEVE I trial)
- Lipton RB et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887-1898.
- Ailani J et al. Ubrogepant for acute treatment of migraine: efficacy and safety in the presence of common comorbidities and concomitant medications. Headache. 2021;61(2):357-368.
- Scott LJ. Ubrogepant: first approval. Drugs. 2020;80(3):323-328.
Already have test results?
If you've accumulated years of normal tests but still have migraines, those records may contain patterns that haven't been examined together.
Related reading
This is educational content, not medical advice. Always consult a qualified clinician.